Tom Anderson

Tom Anderson brings a unique skill set to ExpressCells: managing aggressive growth, IPO, financing, fundraising, and talent development. Mr. Anderson was recruited to Sage Therapeutics, Inc. in 2014 to be the company’s first Chief Commercial Strategy Officer. After the successful launch of ZULRESSO™ (brexanolone), he left Sage to found his own strategic advisory firm, TreD Avon Advisors, LLC. Between 2004 and 2014, Mr. Anderson was a senior operating (P&L) executive with Shire Pharmaceuticals Group in a number of strategic, CEO-advisory roles. During that time, Shire achieved a 5-fold increase in revenues and market cap valuation. Prior to that, Mr. Anderson was with J&J. Between 2000 and 2002, he served in C-suite and Board roles with market-leading consumer product companies as part of the Claneil Enterprises, Inc. family of companies: President & CEO for Ranir-DCP Corporation, and EVP / COO with Claneil’s Lander Company, Inc. Mr. Anderson earned an MBA from the University of Notre Dame’s Mendoza College of Business Administration. He received a BS in civil engineering from the P.C. Rossin College of Engineering at Lehigh University.